IceCure Medical reported a 26% increase in total revenue to $2.6 million for the first nine months of 2026, driven by an 83% surge in U.S. sales. Despite this commercial expansion and a broader footprint across 21 states, the company's net loss widened to $12.9 million from $10.8 million in the prior-year period, with cash reserves totaling $8.2 million as of September 30, 2026.
Nine-month revenues rose 26% to $2.6 million with U.S. ProSense sales up 83% and commercial reach doubling to 21 states, which is clearly positive. However, net loss widened to $12.9 million from $10.8 million and R&D spend grew to $6.5 million, while cash of only $8.2 million raises funding questions. The good and bad largely offset each other.
- • Nine-month revenues up 26% to $2.6 million versus $2.1 million in 2025
- • U.S. sales grew 83% year over year and commercial reach expanded from 11 to 21 states
- • Net loss widened to $12.9 million from $10.8 million year over year
- • Cash and cash equivalents of only $8.2 million as of September 30, 2026 against ongoing losses